2024
A multi‐institutional survey of apheresis services among institutions in the United States
Yurtsever N, Jacobs J, Booth G, Schwartz J, Park Y, Woo J, Lauro D, Torres S, Ward D, Stephens L, Allen E, Tormey C, Adkins B. A multi‐institutional survey of apheresis services among institutions in the United States. Journal Of Clinical Apheresis 2024, 39: e22138. PMID: 38979705, DOI: 10.1002/jca.22138.Peer-Reviewed Original ResearchMeSH KeywordsBlood Component RemovalCOVID-19HumansPandemicsPlasma ExchangeSARS-CoV-2Surveys and QuestionnairesUnited StatesConceptsTherapeutic plasma exchangeRed blood cell exchangeCell collectionSpectra Optia apheresis systemMulti-institutional surveyHematopoietic progenitor cell collectionProgenitor cell collectionUS academic centersCAR-TPlasma exchangeApheresis therapyGene therapyTransfusion medicine serviceCellular therapyApheresis practiceApheresis systemCell exchangeAcademic medical centerClinical trialsAcademic centersHPC-AApheresisMedical CenterTherapyCoronavirus disease 2019
2022
Assessment of polymicrobial interactions in bacterial isolates from transfused platelet units associated with sepsis
Kerantzas CA, Merwede J, Snyder EL, Hendrickson JE, Tormey CA, Kazmierczak BI, Peaper DR. Assessment of polymicrobial interactions in bacterial isolates from transfused platelet units associated with sepsis. Transfusion 2022, 62: 2458-2463. PMID: 36178430, PMCID: PMC11472026, DOI: 10.1111/trf.17136.Peer-Reviewed Original ResearchConceptsAcinetobacter calcoaceticus-baumannii complexBlood productsS. saprophyticusPlatelet unitsContaminated blood productsCDC investigationsApheresis platelet productsTransfusion reactionsPolymicrobial contaminationPlatelet productsDisease controlBacterial isolatesStudy designStaphylococcus saprophyticusPolymicrobial interactionsCDC casesSaprophyticusFuture studiesPotential interactionsCommon sourceSepsisIsolatesCasesCoaggregationEfficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients
Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, Li Y, Wu D, Cobb GF, Baptiste G, O’Keeffe M, Corpuz MO, Ostrosky-Zeichner L, Amin A, Zacharioudakis IM, Jayaweera DT, Wu Y, Philley JV, Devine MS, Desruisseaux MS, Santin AD, Anjan S, Mathew R, Patel B, Nigo M, Upadhyay R, Kupferman T, Dentino AN, Nanchal R, Merlo CA, Hager DN, Chandran K, Lai JR, Rivera J, Bikash CR, Lasso G, Hilbert TP, Paroder M, Asencio AA, Liu M, Petkova E, Bragat A, Shaker R, McPherson DD, Sacco RL, Keller MJ, Grudzen CR, Hochman JS, Pirofski LA, Rahman F, Ajayi A, Rodriguez S, Ledesma A, Keeling D, Rappoport N, Ebel S, Kim J, Chang M, Chan K, Patel P, Martocci A, Dave S, Darwish Y, Taveras M, Shoyelu V, Xin P, Iturrate E, Moldolsky L, Raimondo B, Mendez S, Hughes P, Sterling S, Lord A, Yaghi S, Veloso K, Sheikh M, Visconti-Ferrara E, Fleming A, Youn H, Jane Fran B, Medina R, McKell R, Khan S, Hamilton T, Sanchez C, Patel N, Cleare L, Vergnolle O, Nakouzi A, Quevedo G, Bortz R, Wirchnianski A, Florez C, Babb R, Ayala J, Tsagaris K, James A, Eke I, Obeidallah A, Sandu O, Sohval S, Serrano-Rahman L, Uehlinger J, Bartash R, Al-Abduladheem A, Gendlina I, Sheridan C, Bortnick A, Eichler J, Kaufman R, Yukelis S, Pennock M, Goggin M, Shen C, Annam J, Khokhar A, Barboto D, Lally B, Lee A, Lee M, Yang X, Allen S, Malaviya A, Moussa O, Park R, Sample R, Bae A, Benoni G, Boerger L, Baker L, Luther M, Ameti L, Briggs N, Golden M, Gormally M, Huang G, Johnson R, Morrison A, Montagna-Hill M, Rivera B, Cortezzo G, Debski K, Nicoletti, DeBenedictis K, Davis R, Marshall C, Duque Cuartas M, Beauchamps L, Bertran-Lopez J, Gonzales Zamora J, Delgado-Lelievre M, Dominguez S, Lee C, Kusack H, Karakeshishyan V, Hajaz A, Deniz D, Garcia G, Dae K, Blenet P, Jaffe D, Olson L, Sabogal D, Blust O, Del Prete Perez V, Bornia C, Rodriguez-Perez V, Calderon V, Ramdev R, Jolly A, Guzman I, Guerra R, Brito S, Hobbs R, Denham R, Dick J, Hernandez M, Nielsen L, Anjum S, Mader S, Stutz T, Mammadova M, Nichols P, Khan T, Boktour M, Castaneda B, Benitez B, Hinojosa E, Guerra B, Ortiz A, Hebbeler-Clark R, McShane P, Hibbard R, Hawkins B, Dohanich E, Wadle C, Greenlee K, Brooks J, Herrick C, Gode A, Bergl P, Hu K, Patel J, Srinivasan S, Graf J, Klis C, Reimer K, Carpenter E, Naczek C, Petersen R, Dex R, Drossart J, Zelten J, Brummitt C, Liang M, Yanny L, Dennison G, Runningen P, Brzezinski B, Fiebig S, Naczek C, Kasdorf M, Parameswaran L, Corcoran A, Rohatgi A, Wronska M, Wu X, Srinivasan R, Deng F, Filardo T, Pendse J, Blaser S, Whyte O, Gallagher J, Thomas O, Ramos D, Sturm-Reganato C, Fong C, Daus I, Payoen A, Chiofolo J, Friedman M, Wu D, Jacobson J, Schneider J, Sarwar U, Wang H, Huebinger R, Dronavalli G, Bai Y, Grimes C, Eldin K, Umana V, Martin J, Heath T, Bello F, Ransford D, Laurent-Rolle M, Shenoi S, Akide-Ndunge O, Thapa B, Peterson J, Knauf K, Patel S, Cheney L, Tormey C, Hendrickson J. Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients. JAMA Internal Medicine 2022, 182: 115-126. PMID: 34901997, PMCID: PMC8669605, DOI: 10.1001/jamainternmed.2021.6850.Peer-Reviewed Original ResearchConceptsCCP recipientsPlacebo recipientsSecondary outcomesSymptom durationHospitalized patientsPrimary outcomeDay 28COVID-19SARS-CoV-2 serostatusSARS-CoV-2 titersWorld Health Organization (WHO) ordinal scaleCOVID-19 convalescent plasmaConvalescent plasma usePlacebo-controlled trialLess daysExploratory subgroup analysisNon-Hispanic blacksSARS-CoV-2CCP efficacyConcomitant medicationsAdverse eventsClinical improvementSymptom onsetConvalescent plasmaMedian age
2021
Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
Goshua G, Sinha P, Hendrickson J, Tormey C, Bendapudi PK, Lee AI. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood 2021, 137: 969-976. PMID: 33280030, PMCID: PMC7918179, DOI: 10.1182/blood.2020006052.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCombined Modality TherapyCost-Benefit AnalysisDecision TreesDrug CostsDrug Therapy, CombinationFemaleFibrinolytic AgentsHemorrhageHumansImmunosuppressive AgentsLength of StayMaleMarkov ChainsMiddle AgedModels, EconomicMulticenter Studies as TopicPlasma ExchangePurpura, Thrombotic ThrombocytopenicRecurrenceRituximabSingle-Domain AntibodiesStandard of CareUnited StatesYoung AdultConceptsIncremental cost-effectiveness ratioThrombotic thrombocytopenic purpuraTherapeutic plasma exchangeVon Willebrand factorRelapse rateThrombocytopenic purpuraClinical trialsMajor randomized clinical trialsThrombotic microangiopathy leadingEnd-organ damageWillebrand factorPlatelet count recoveryRandomized clinical trialsHealth system costsOne-way sensitivity analysesCost-effectiveness ratioLife-threatening diseaseProbabilistic sensitivity analysesCost-effectiveness analysisHospital lengthCount recoveryPlasma exchangeTPE treatmentTTP patientsImmunomodulatory agents
2017
How do we perform and bill for blood bank physician consultative services?
Jhang JS, Francis RO, Winkler A, Tormey C. How do we perform and bill for blood bank physician consultative services? Transfusion 2017, 57: 2311-2318. PMID: 28833250, DOI: 10.1111/trf.14264.Peer-Reviewed Original ResearchMeSH KeywordsBlood BanksFees and ChargesHumansPhysiciansReferral and ConsultationUnited StatesWorkforceConceptsIndividual patientsTertiary care teaching hospitalCurrent Procedural Terminology codesPhysician servicesTransfusion medicine physiciansProcedural Terminology codesHealth care providersComponent therapyProvider educationTransfusion reactionsBlood productsTeaching hospitalClinical significanceInappropriate testingCare providersMedicine physiciansTerminology codesApheresis proceduresPatientsPhysiciansConsultative servicesLaboratory test resultsHealth careMedical servicesMedical direction
2014
The Development and Implementation of, and First Years' Experience With, a Massive/Emergency Transfusion Protocol (Damage Control Hematology Protocol) in a Veterans Affairs Hospital
Gehrie EA, Tormey CA. The Development and Implementation of, and First Years' Experience With, a Massive/Emergency Transfusion Protocol (Damage Control Hematology Protocol) in a Veterans Affairs Hospital. Military Medicine 2014, 179: 1099-1105. PMID: 25269127, DOI: 10.7205/milmed-d-14-00045.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBlood BanksBlood Grouping and CrossmatchingBlood Loss, SurgicalBlood TransfusionClinical AuditClinical ProtocolsConnecticutEmergenciesErythrocyte TransfusionFactor VIIaFactor VIIIFibrinogenHematemesisHospitals, VeteransHumansLaboratories, HospitalMalePlasma ExchangePlatelet TransfusionPostoperative HemorrhageRetrospective StudiesUnited StatesUnited States Department of Veterans AffairsConceptsFresh frozen plasmaRecombinant factor VIIaRed blood cellsVeterans Affairs hospitalTransfusion protocolFactor VIIaUnits of RBCsVeterans Affairs Connecticut Healthcare SystemUnits of FFPLarge trauma centersHospital-based blood banksETP patientsMassive transfusionTrauma centerFrozen plasmaSeparate patientsPatientsWest HavenBleeding emergenciesBlood bankBlood cellsYears' experienceHealthcare systemPlateletsHospital
2009
Estimation of Combat-Related Blood Group Alloimmunization and Delayed Serologic Transfusion Reactions in U.S. Military Veterans
Tormey CA, Stack G. Estimation of Combat-Related Blood Group Alloimmunization and Delayed Serologic Transfusion Reactions in U.S. Military Veterans. Military Medicine 2009, 174: 503-507. PMID: 20731281, DOI: 10.7205/milmed-d-02-5808.Peer-Reviewed Original ResearchConceptsSerologic transfusion reactionsTransfusion reactionsVeterans Affairs Medical CenterAnamnestic immune responseMilitary veteran patientsBlood group alloantibodiesMilitary veteransPre-existing antibodiesU.S. military veteransAlloimmunization ratePrior alloimmunizationVeteran patientsTransfusion recordsVA careImmune responseMedical CenterAlloimmunizationAlloantibodiesVeteransAntibodiesHigh rateTransfusionPatientsPrevalenceCare
2008
Red blood cell alloantibody frequency, specificity, and properties in a population of male military veterans
Tormey CA, Fisk J, Stack G. Red blood cell alloantibody frequency, specificity, and properties in a population of male military veterans. Transfusion 2008, 48: 2069-2076. PMID: 18631165, DOI: 10.1111/j.1537-2995.2008.01815.x.Peer-Reviewed Original ResearchConceptsRBC alloantibodiesMale military veteransDecade of birthMilitary veteransVA careRed blood cell alloantibodiesVeterans Affairs Medical CenterHospital-based patientsPercent of casesLarge male predominanceRace/ethnicityAlloantibody frequenciesAlloantibody specificitiesFrequent alloantibodiesTransfusion historyMale predominanceD alloimmunizationTransfusion recordsHigh prevalenceMedical CenterAlloantibodiesAntibody developmentAlloimmunizationAntiglobulin phasePrevalence